Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has been assigned a consensus rating of “Buy” from the eight brokerages that are covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $17.29.

Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a report on Friday, November 22nd. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. BMO Capital Markets upped their price target on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. Finally, Jefferies Financial Group lifted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th.

Replimune Group Trading Down 6.8 %

Replimune Group stock opened at $11.20 on Wednesday. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The firm’s 50 day moving average price is $12.42 and its two-hundred day moving average price is $11.11. The firm has a market cap of $766.27 million, a price-to-earnings ratio of -3.67 and a beta of 1.28. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. On average, research analysts predict that Replimune Group will post -2.91 EPS for the current fiscal year.

Insider Buying and Selling at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Several large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its holdings in Replimune Group by 3.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company’s stock worth $2,733,000 after purchasing an additional 8,074 shares during the last quarter. Barclays PLC grew its stake in Replimune Group by 165.5% in the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after buying an additional 98,791 shares during the last quarter. Geode Capital Management LLC raised its holdings in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after acquiring an additional 217,308 shares during the period. State Street Corp lifted its position in Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after acquiring an additional 1,182,181 shares during the last quarter. Finally, Parkman Healthcare Partners LLC boosted its holdings in Replimune Group by 45.5% during the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after acquiring an additional 238,747 shares during the period. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.